Ariad Pharmaceuticals Inc fka ARIA

[lax20m]

The evidence that Briga won't be first line "right out of the starting gate" is that the clinical trial results which will be used to file Briga's NDA and grant it FDA approval was not designed to evaluate the drug in a first line setting and therefor the label will not be for first line use.